JP5340160B2 - プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 - Google Patents

プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 Download PDF

Info

Publication number
JP5340160B2
JP5340160B2 JP2009535559A JP2009535559A JP5340160B2 JP 5340160 B2 JP5340160 B2 JP 5340160B2 JP 2009535559 A JP2009535559 A JP 2009535559A JP 2009535559 A JP2009535559 A JP 2009535559A JP 5340160 B2 JP5340160 B2 JP 5340160B2
Authority
JP
Japan
Prior art keywords
diagnosis
copeptin
provasopressin
neurophysin
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009535559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509576A5 (enExample
JP2010509576A (ja
Inventor
アンドレアス ベルクマン，
ニールス モルゲンターラー，
ヤナ パパッソチロー，
ヨアキム ストラック，
ビート ミュラー，
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲーエムベーハー filed Critical ベー．エル．アー．ハー．エム．エス ゲーエムベーハー
Publication of JP2010509576A publication Critical patent/JP2010509576A/ja
Publication of JP2010509576A5 publication Critical patent/JP2010509576A5/ja
Application granted granted Critical
Publication of JP5340160B2 publication Critical patent/JP5340160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009535559A 2006-11-12 2007-11-11 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 Active JP5340160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006053442A DE102006053442A1 (de) 2006-11-12 2006-11-12 Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006053442.5 2006-11-12
PCT/DE2007/002037 WO2008058517A2 (de) 2006-11-12 2007-11-11 Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013000176A Division JP2013083664A (ja) 2006-11-12 2013-01-04 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化

Publications (3)

Publication Number Publication Date
JP2010509576A JP2010509576A (ja) 2010-03-25
JP2010509576A5 JP2010509576A5 (enExample) 2010-11-25
JP5340160B2 true JP5340160B2 (ja) 2013-11-13

Family

ID=39277664

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009535559A Active JP5340160B2 (ja) 2006-11-12 2007-11-11 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化
JP2013000176A Pending JP2013083664A (ja) 2006-11-12 2013-01-04 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化
JP2015151852A Active JP6170101B2 (ja) 2006-11-12 2015-07-31 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013000176A Pending JP2013083664A (ja) 2006-11-12 2013-01-04 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化
JP2015151852A Active JP6170101B2 (ja) 2006-11-12 2015-07-31 プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化

Country Status (10)

Country Link
US (3) US8158368B2 (enExample)
EP (2) EP2089718B1 (enExample)
JP (3) JP5340160B2 (enExample)
CN (2) CN105092858A (enExample)
AT (1) ATE522814T1 (enExample)
DE (1) DE102006053442A1 (enExample)
DK (1) DK2378290T3 (enExample)
ES (2) ES2634137T3 (enExample)
HK (1) HK1215731A1 (enExample)
WO (1) WO2008058517A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
ES2652027T3 (es) 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
US20120329666A1 (en) * 2009-10-05 2012-12-27 Duke University Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use
EP2776064A4 (en) 2011-11-11 2015-08-05 Woomera Therapeutics ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
WO2023191145A1 (ko) 2022-03-31 2023-10-05 (주)네오닉스 배터리팩

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
DE10027954A1 (de) 1999-12-22 2001-06-28 Dade Behring Marburg Gmbh Humanes Procalcitonin, dessen Herstellung und Verwendung
ES2280170T3 (es) 1999-12-22 2007-09-16 Dade Behring Marburg Gmbh Soluciones de procalcitonina humana.
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
JP2006505510A (ja) * 2002-07-16 2006-02-16 ウーメラ セラピューティックス， インク． プロバソプレシン発現癌細胞の同定および治療のための組成物およびその利用
AU2003302340B8 (en) * 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
GB0401730D0 (en) * 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
EP1628136A1 (en) 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102004047968A1 (de) * 2004-10-01 2006-04-06 B.R.A.H.M.S Ag Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
JP4983525B2 (ja) * 2007-10-11 2012-07-25 住友電装株式会社 ワイヤハーネスのプロテクタ取付構造
US9229013B2 (en) * 2009-05-05 2016-01-05 B.R.A.H.M.S Gmbh Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction

Also Published As

Publication number Publication date
US10718783B2 (en) 2020-07-21
WO2008058517A2 (de) 2008-05-22
WO2008058517A3 (de) 2008-10-23
ES2634137T3 (es) 2017-09-26
US20170059583A1 (en) 2017-03-02
CN105092858A (zh) 2015-11-25
ES2370071T3 (es) 2011-12-12
EP2378290B1 (de) 2017-05-03
ATE522814T1 (de) 2011-09-15
US20120270245A1 (en) 2012-10-25
JP6170101B2 (ja) 2017-07-26
DE102006053442A1 (de) 2008-05-15
US8158368B2 (en) 2012-04-17
DK2378290T3 (en) 2017-07-31
JP2016026286A (ja) 2016-02-12
EP2089718A2 (de) 2009-08-19
HK1215731A1 (zh) 2016-09-09
JP2010509576A (ja) 2010-03-25
CN101563613A (zh) 2009-10-21
EP2378290A1 (de) 2011-10-19
EP2089718B1 (de) 2011-08-31
JP2013083664A (ja) 2013-05-09
US20100041064A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
JP6170101B2 (ja) プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化
JP5663531B2 (ja) 心不全を伴う気道および肺の感染または炎症性疾患の診断
US11241395B2 (en) Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
ES2369977T3 (es) Utilización de la procalcitonina (pct) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa.
US20210285968A1 (en) Proadm and/or histones as markers indicating an adverse event
CN102782501B (zh) 在无症状患者中基于il-6检测的全身炎性应答综合征和败血症的早期诊断和预测
JP2010509576A5 (enExample)
JP2022553420A (ja) 敗血症管理
JP2015068760A (ja) 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
ES2807960T3 (es) Método para diagnosticar infecciones pulmonares postoperatorias en pacientes que se sometieron a cirugía
HK1135183A (en) Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii
HK1137807B (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
HK40029756B (zh) 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程
JPWO2022245920A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120424

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130806

R150 Certificate of patent or registration of utility model

Ref document number: 5340160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250